Canaccord Genuity Maintains Buy on Castle Biosciences, Raises Price Target to $50

Benzinga · 3d ago
Canaccord Genuity analyst Kyle Mikson maintains Castle Biosciences (NASDAQ:CSTL) with a Buy and raises the price target from $37 to $50.